NKTRNektar Therapeutics

NKTR Stock Price, Valuation & Chart | Nektar Therapeutics

Compare

$71.750+0.37 (+0.52%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology NKTR intrinsic value NKTR calculated fair value vs price

Overview Financials Dividends Ratios

NKTR Historical price chart

NKTR Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization2.06B

PE Ratio-10.74

EPS-6.68

Trading Volume301.03K

Today's High/Low72.72/70.41

Dividend Yield0.00

52 Week High/Low109.0/27.87

Shares Outstanding28.69M

NKTR Financial Statement

NKTR Analyst ratings

NKTR Analysis & performance metrics

NKTR Company profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The…

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive…

NKTR Management team

Name

Position

Howard W. RobinCEO

Chief Executive Officer, President & Director

Mark A. Wilson J.D.

Senior Vice President, Chief Legal Officer & Secretary

Jonathan Zalevsky Ph.D.

Senior Vice President and Chief Research & Development Officer

Sandra A. GardinerCFO

Chief Financial Officer and Principal Financial & Accounting Officer

Brian L. Kotzin M.D.

Interim Chief Medical Officer

Jason Barnard

Chief Accounting Officer

Robert Bacci

Chief People Officer and Head of Quality & Facilities

Jennifer Ruddock

Chief Business Officer

Name

Position

Howard W. RobinCEO

Chief Executive Officer, President & Director

Mark A. Wilson J.D.

Senior Vice President, Chief Legal Officer & Secretary

Jonathan Zalevsky Ph.D.

Senior Vice President and Chief Research & Development Officer

Sandra A. GardinerCFO

Chief Financial Officer and Principal Financial & Accounting Officer

Brian L. Kotzin M.D.

Interim Chief Medical Officer

Jason Barnard

Chief Accounting Officer

Robert Bacci

Chief People Officer and Head of Quality & Facilities

Jennifer Ruddock

Chief Business Officer

Management Team

Howard W. RobinCEO

Chief Executive Officer, President & Director

Mark A. Wilson J.D.

Senior Vice President, Chief Legal Officer & Secretary

Jonathan Zalevsky Ph.D.

Senior Vice President and Chief Research & Development Officer

Sandra A. GardinerCFO

Chief Financial Officer and Principal Financial & Accounting Officer

Brian L. Kotzin M.D.

Interim Chief Medical Officer

Jason Barnard

Chief Accounting Officer

Robert Bacci

Chief People Officer and Head of Quality & Facilities

Jennifer Ruddock

Chief Business Officer

Management

Howard W. RobinCEO

Chief Executive Officer, President & Director

Mark A. Wilson J.D.

Senior Vice President, Chief Legal Officer & Secretary

Jonathan Zalevsky Ph.D.

Senior Vice President and Chief Research & Development Officer

Sandra A. GardinerCFO

Chief Financial Officer and Principal Financial & Accounting Officer

Brian L. Kotzin M.D.

Interim Chief Medical Officer

Jason Barnard

Chief Accounting Officer

Robert Bacci

Chief People Officer and Head of Quality & Facilities

Jennifer Ruddock

Chief Business Officer

Total 8 executives

NKTR Frequently asked questions

What is Nektar Therapeutics (NKTR) Stock Price?

Current stock price of Nektar Therapeutics (NKTR) stock is $71.750. The stock price is +0.52% higher in the session. The intraday range can be seen from this page. Volume of Nektar Therapeutics (NKTR) stock is 301.03K.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the Nektar Therapeutics (NKTR) stock price going up or down today?

The stock price of Nektar Therapeutics (NKTR) can change with earnings, company news, and overall market sentiment. Nektar Therapeutics operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Nektar Therapeutics stock expensive at its current price?

Whether Nektar Therapeutics looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for NKTR on this page is -10.74. EPS on this page is -6.68. Compare those figures with peers and growth expectations before deciding if the current Nektar Therapeutics price is justified.

How has the stock price of Nektar Therapeutics (NKTR) performed historically?

Historical performance for Nektar Therapeutics (NKTR) is shown on the price chart on this page. Review multi-period moves alongside volume to see how NKTR reacted to past earnings and market events.

Should I buy Nektar Therapeutics (NKTR) stock, at this price?

Buying Nektar Therapeutics (NKTR) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.